No abstract

Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people’s health and lives, and increasing public health care expenses. Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases. Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight. Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels. However, given the safety or effectiveness concerns of anti-obesity drugs, many of the currently used drugs have limited clinical use. Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves, islets, heart, lung, skin, and other organs. Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity. Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals. This review describes evidence from previous research on the effects of GLP-1R agonists on obesity. We anticipate that this review will generate data that will help biomedical researchers or clinical workers develop obesity treatments based on GLP-1R agonists.

Combinations of nanoparticles and surfactants have been widely employed in many industrial processes, i.e., boiling and condensation in heat transfer and hydraulic fracturing in shale oil and gas production, etc. However, the underlying mechanism for various phenomena resulting from the addition of nanoparticles into the surfactant solutions is still unclear. For instance, there are contradictory conclusions from the literature regarding the variations of surface tension upon the addition of nanoparticles into surfactant solutions. In this work, the dominating factors determining if the surface activity of the surfactant solution will increase or conversely decrease when adding certain kinds of nanoparticles have been investigated. Two typical hydrophilic nanoparticles, SiO2 and TiO2 with anionic or cationic surfactants, respectively, have been considered. The surface tension has been measured in a wide range of nanoparticle and surfactant concentrations. It was found that the surface tension of the ionic surfactant solution can be further reduced only if nanoparticles of the same charge were added. For instance, a system containing 0.25 CMC SDS and 1 wt% SiO2 behaves similar to a 0.34 CMC SDS-only solution. Interestingly, the observed synergistic effect is found to be more significant if the surfactant concentration is much lower than its CMC for a given nanoparticle content. Moreover, the effect is perfectly reversible. When the nanoparticles were separated from the system, the surface tension values recovered fully to that of the pure surfactants. If nanoparticles of opposite charge were added, however, the surface tension of the surfactant solution increased. Zeta potential measurement and centrifugal treatment have been employed to reveal the interplay between nanoparticles and surfactants and the adsorption behavior of their assemblies at the liquid/air interface. Based on the experimental outcomes, a possible physical mechanism was proposed. It was concluded that the electrostatic repulsion between surfactant molecules and nanoparticles should be the dominant factor responsible for the observed reversible synergistic effect. Our study is expected to contribute to a better understanding of the interfacial phenomenon in nanoparticle-surfactant complex systems.

No abstract

Introduction To investigate the effect of dose maintenance, reduction, or discontinuation of the etanercept biosimilar Yisaipu (YSP) on early axial spondyloarthritis (axSpA) patients in remission with YSP 50 mg once weekly (QW). Material and methods Patients were enrolled in three groups: full dose (YSP50), half dose (YSP25), and discontinuation (YSP0). Patients were assessed by the same rheumatologist every 8 weeks for 48 weeks. The primary endpoint was the proportion of non-failure patients in each group. If a flare occurred during the study period, the patient resumed YSP 50 mg QW or was switched to another tumor necrosis factor inhibitor. Results A total of 144 patients were included and each group included 48 patients. The proportion of non-failure patients was significantly greater in the YSP50 group than in the YSP0 group at 48 weeks (91.7% vs. 72.9%, p = 0.032). The difference in the other two comparisons was not statistically significant (YSP50 vs. YSP25 group, p = 0.522; YSP25 vs. YSP0 group, p = 0.132). The median time to flare did not differ significantly between the three groups ( p > 0.05). Most patients who flared regained remission rapidly after resuming YSP 50 mg QW or starting adalimumab 40 mg every other week. Conclusions For patients with early axSpA in remission on YSP for more than 12 weeks, continuation of YSP at full dose was superior to discontinuation of YSP, but not superior to halving the dose.